orbofiban has been researched along with Apoplexy in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 3 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Cannon, CP; Feske, SK; Murphy, S; Schwamm, LH; Smith, EE | 1 |
Alexander, JC; Anders, RJ; Berink, P; Braunwald, E; Cannon, CP; Caspi, A; Charlesworth, A; Langer, A; Lopez-Sendon, J; McCabe, CH; Skene, A; Toman, J; Wilcox, RG | 1 |
Byrne, CE; Cannon, CP; Fitzgerald, AP; Fitzgerald, DJ; Kenny, D; Moran, B; Muckian, C; O'Neill, PA; Shields, DC | 1 |
3 trial(s) available for orbofiban and Apoplexy
Article | Year |
---|---|
Risk factors for stroke after acute coronary syndromes in the Orbofiban in Patients with Unstable Coronary Syndromes--Thrombolysis In Myocardial Infarction (OPUS-TIMI) 16 study.
Topics: Aged; Alanine; Angina, Unstable; Aspirin; Cerebral Hemorrhage; Female; Fibrinolytic Agents; Follow-Up Studies; Humans; Ischemic Attack, Transient; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Proportional Hazards Models; Pyrrolidines; Risk Factors; Stroke; Syndrome; Thrombolytic Therapy | 2006 |
Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial.
Topics: Administration, Oral; Alanine; Anticoagulants; Aspirin; Coronary Disease; Double-Blind Method; Female; Follow-Up Studies; Heparin; Humans; Intracranial Hemorrhages; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrrolidines; Stroke; Survival Analysis; Thrombocytopenia; Treatment Outcome | 2000 |
The contribution of genetic factors to thrombotic and bleeding outcomes in coronary patients randomised to IIb/IIIa antagonists.
Topics: Alanine; Coronary Disease; Genotype; Glycoproteins; Hemorrhage; Humans; Myocardial Infarction; Myocardial Revascularization; Platelet Glycoprotein GPIIb-IIIa Complex; Polymorphism, Genetic; Pyrrolidines; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; Risk Assessment; Stroke; Thrombosis; Treatment Outcome | 2002 |